TEIPP Immunotherapy in Patients With NSCLC
NCT05898763
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
26
Enrollment
OTHER
Sponsor class
Conditions
Non Small Cell Lung Cancer
Interventions
DRUG:
TEIPP24 (LRPAP7-30V-SLP vaccine in Montanide ISA-51)
Sponsor
Erasmus Medical Center